US FDA gives Atia Vision go-ahead to begin clinical study of the OmniVu Lens System

Study suggests that teprotumumab may have fewer adverse outcomes than glucocorticoids when treating thyroid eye disease. Photo: Bobby Saenz, OD. Click image to enlarge. The insulin-like growth factor-1 receptor inhibitor teprotumumab has proven effective for thyroid eye disease (TED), but there is limited evidence on its long-term safety. In a recent study, researchers inves